Skip to Main content Skip to Navigation
Poster communications

Cell-of-Origin (COO) Classification, BCL2 and MYC Expression Associated Outcome in Younger Patients Treated By RCHOP Front-Line Therapy Versus Intensive Regimen Followed By Autologous Transplant for De Novo Advanced Diffuse Large B Cell Lymphoma (DLBCL) : Results of the French Prospective Multicenter Randomized Trial Goelams-075

Gaëlle Laboure 1 Marie-Cecile Parrens 1 Anjarasoa Tsaranazy 1 Magali Bordier 1 Steven Le Gouill 2 Vincent Delwail 3 Rémy Gressin 4, 5 Jerome Cornillon 6 Gandhi Damaj 7 Charles Yves Foussard 8 Hervé Maisonneuve 9 Eric Deconinck 10 Guillaume Cartron 11, 12 François Dreyfus 13 Emmanuel Gyan 14, 15 Laurent Sutton 16 Nadine Morineau 17 Magda Alexis 18 Anne Banos 19 Diane Damotte 20, 21 Anne Moreau 2 Françoise Kraeber-Bodéré 22, 23, 24 Delphine Rossille 25, 26 Thierry Fest 26 Thierry Lamy 27, 26 Noel Milpied 28
Abstract : The prognostic value of COO classification by immunohistochemistry (IHC) for de novo untreated advanced DLBCL remains controversial after Rituximab-based frontline therapy. Other biomarkers such as BCL2 or MYC protein expression have been proposed to predict survival. IHC characteristics were investigated in a large multicenter randomized study.
Complete list of metadatas

https://hal-univ-rennes1.archives-ouvertes.fr/hal-01290432
Contributor : Laurent Jonchère <>
Submitted on : Wednesday, May 24, 2017 - 4:15:20 PM
Last modification on : Saturday, October 24, 2020 - 3:38:48 AM

File

Abstract ASH IHC GOELAMS075-fu...
Files produced by the author(s)

Identifiers

  • HAL Id : hal-01290432, version 1

Citation

Gaëlle Laboure, Marie-Cecile Parrens, Anjarasoa Tsaranazy, Magali Bordier, Steven Le Gouill, et al.. Cell-of-Origin (COO) Classification, BCL2 and MYC Expression Associated Outcome in Younger Patients Treated By RCHOP Front-Line Therapy Versus Intensive Regimen Followed By Autologous Transplant for De Novo Advanced Diffuse Large B Cell Lymphoma (DLBCL) : Results of the French Prospective Multicenter Randomized Trial Goelams-075. 55th Annual Meeting and Exposition of the American-Society-of-Hematology, Dec 2013, La Nouvelle Orléans, United States. 126 (23), pp.3920, 2015. ⟨hal-01290432⟩

Share

Metrics

Record views

1036

Files downloads

256